ECL — Ecolab Inc.

Sell-side sentiment is decidedly positive: 29 buy ratings against 7 holds and 1 sell, with a $326.13 average price target (recent-avg $331.50) implying roughly 18% upside from the 2026-09-13 close of $276.18. The anchor is the July 28, 2026 Q2 print - adjusted diluted EPS of $2.09 vs. $2.08 consensus, +11% YoY, 5% organic sales growth (4% price, 1% volume), organic operating margin up 40bp to 18.8%, and raised full-year guidance. The tape disagrees with the analysts, though: as of 2026-09-13 ECL was -1.11% over one week and -0.81% over one month, suggesting the beat was already discounted after a run to a 52-week high of $309.27.

Revenue growth has inflected higher, and this is a trend, not a blip: YoY growth was -1.5% in Q1 2025 ($3,695M), +1.0% in Q2 2025 ($4,025M), +4.2% in Q3 2025 ($4,165M), +4.8% in Q4 2025 ($4,196M), +10.0% in Q1 2026 ($4,066M) and +9.7% in Q2 2026 ($4,415M). The important caveat is composition - management framed Q2 2026 organic growth as only 5% (4 points price, 1 point volume), so roughly half the reported acceleration is acquired or FX. The balance sheet corroborates that: total assets jumped from $25.0B (Mar 2026) to $29.9B (Jun 2026) as long-term debt rose from $6.92B to $11.91B with $5.14B of cash parked on the books. Profitability splits in two directions: reported operating margin actually slipped YoY in both H1 2026 quarters (Q1 15.3% vs. 15.9%; Q2 17.2% vs. 17.6%), while company-defined organic operating margin expanded 40bp to 18.8% and adjusted EPS grew 11% versus GAAP EPS growth of just 3.3% ($1.90 vs. $1.84) - a $0.19/share gap from amortization and items that repeat every quarter. TTM operating margin is 17.4%, up only ~26bp from 17.1% a year earlier. Earnings quality is genuinely high: operating cash flow exceeded net income in 11 of the last 12 quarters, the accruals ratio is -0.65%, and TTM free cash flow of $1,874M was up ~19% YoY.

Fair-to-full, not cheap. As of 2026-09-13, the trailing P/E of 36.8x sits about 11% below Ecolab's own 5-year average of 41.18x, but P/S of 4.62x is about 11% above the 5-year average of 4.15x - a genuinely mixed signal rather than a uniform discount. On the $8.155 next-FY consensus EPS, the forward P/E is ~33.9x, which against ~10-11% adjusted EPS growth implies a PEG near 3.0 - a full price for a business compounding organically at mid-single digits. The most honest valuation tells: TTM free cash flow of $1,874M against a $77.7B market cap is a 2.4% FCF yield, and EV/EBITDA is 26.0x. You are paying a quality premium, not a value multiple. Note the reported PEG of -69.4 is statistical noise (the growth input is distorted by Q3 2024, when net income of $736.5M exceeded that quarter's $707.2M operating income on a non-operating gain) and should be discarded.

The stock is being priced on the adjusted earnings story, not the reported one. In Q2 2026, GAAP diluted EPS rose 3.3% YoY while adjusted EPS rose 11% - the $0.19 gap is amortization and recurring charges, not a one-time event. Meanwhile the 9.7% reported revenue growth decomposes into 5% organic (only 1 point of which is volume) plus roughly 4-5 points of acquisitions and FX. So the ~33.9x forward multiple is capitalizing a durable double-digit EPS growth assumption that is currently being propped up by price and purchased revenue. Two things validate that assumption: (1) volume growth accelerating meaningfully above 1%, and (2) the newly raised $5.14B cash pile and $11.91B of long-term debt converting into accretive earnings rather than just amortization. If Q3 2026 (late October 2026) shows volumes still stuck near 1% and GAAP EPS growth in the low single digits, it is the multiple, not the earnings, that adjusts.

Range-bound and directionless as of 2026-09-13. RSI(14) of 45.29 is neutral - neither oversold nor overbought - and the price sat 1.72% below its 20-day SMA (approximately $281), 0.79% below its 50-day SMA (approximately $278), and 1.12% above its 200-day SMA (approximately $273). Returns: -1.11% (1 week), -0.81% (1 month), +4.06% (3 months), +0.73% (6 months) - a stock consolidating in the high-$260s/low-$280s after backing off the $309.27 52-week high and still far above the $243.15 low. There is no timing edge here: RSI 45 is not a buy trigger, and price is trapped between its short and long moving averages. A pullback that holds the 200-day near $273, or an RSI dip below 35, would be the cleaner entry; a close back above the 50-day on volume would confirm the uptrend resuming.

• Raw material and energy cost volatility: Ecolab's 4 points of Q2 2026 organic growth came almost entirely from price, which is a buffer but also means gross margin (44.1% Q2 2026, down from 44.8% in Q2 2025) is exposed if input costs spike faster than pricing is reset.
• Supply-chain and geopolitical disruption: management cited Middle East-related shipping and supply disruptions as roughly a 1% volume headwind in recent quarters - directly relevant to the already-thin 1% volume growth line.
• Rate/duration sensitivity: with a 0.89 beta but a 36.8x trailing P/E, ECL behaves like a long-duration quality asset - sticky or rising long rates compress the multiple even when operations are fine, which is a plausible explanation for the flat 6-month return.
• End-market bifurcation: softness in heavy industry is being offset by strong Global High-Tech and data-center water/cooling demand, making ECL's growth increasingly dependent on the tech capex cycle rather than broad industrial production.
• FX translation: a large non-US revenue base means dollar strength is a persistent reported-growth headwind, and it is one reason the gap between reported and organic growth numbers can widen or narrow quarter to quarter.

• Q3 2026 earnings, historically late October 2026 - the single most important data point: whether organic volume growth accelerates past 1%, whether organic margin expansion continues, and whether full-year guidance is raised again.
• Deployment of the $5.14B cash balance built in Q2 2026 alongside $11.91B of long-term debt - an acquisition, a paydown, or buybacks will settle the capital allocation question the market has not yet priced.
• Continued Global High-Tech and data-center water/cooling demand plus scaling of the One Ecolab digital/IoT platform, which management frames as the primary offset to industrial softness.
• Price/cost spread: if raw material costs ease while the 4% pricing holds, gross margin recovers from the 44.1% Q2 2026 print and GAAP EPS closes some of the gap to adjusted EPS.
• Sell-side target revisions - if the $326 consensus target drifts toward the $275 low end of the range, sentiment and the multiple follow.

• Volume growth stuck at ~1%: with only 1 point of the 5% organic growth coming from volume, the top line depends on price (which invites customer pushback) and acquisitions (which bring amortization and integration risk).
• The leverage step-up is real and recent: long-term debt nearly doubled sequentially from $6.92B (Mar 2026) to $11.91B (Jun 2026) in a single quarter, taking debt-to-equity to 1.37 and LT debt/equity to 1.18 - the trailing financial-health metrics in the score have not fully absorbed the implications.
• Premium multiple risk: 36.8x trailing, ~33.9x forward, 26.0x EV/EBITDA and a 2.4% FCF yield leave almost no cushion. A slowdown in adjusted EPS growth toward the 3.3% GAAP rate seen in Q2 2026 would likely compress the multiple faster than earnings fall.
• Recurring GAAP-vs-adjusted gap ($0.19/share in Q2 2026): if amortization and charges keep scaling with acquisition activity, reported earnings will keep trailing the narrative investors are actually paying for.
• Exposure to industrial/chemical end-market softness and Middle East supply-chain disruption, both of which hit volume and mix simultaneously.

Ecolab is a genuinely high-quality, pricing-power compounder whose fundamental momentum is improving - revenue growth inflected from -1.5% YoY in Q1 2025 to +9.7% in Q2 2026, adjusted EPS rose 11%, organic operating margin expanded 40bp to 18.8%, free cash flow is up ~19% YoY, and cash generation has exceeded net income in 11 of the last 12 quarters. But at $276.18 on 2026-09-13 you are paying ~33.9x forward earnings and a 2.4% FCF yield for growth that is only half organic and only 1% volume-driven, while the balance sheet just absorbed a ~$5B debt raise. This is a reasonable long-term holding and a name to accumulate on weakness toward the 200-day near $273 - it is not a compelling buy at this price, and the ~18% upside embedded in the $326 sell-side consensus looks too generous.

Two-method cross-check as of 2026-09-13. Method 1: a 33x forward P/E - deliberately below Ecolab's 41.18x five-year average and roughly in line with its 33.9x multiple on FY2026E consensus EPS - applied to my ~$9.00 FY2027E EPS (11% growth off the $8.155 next-FY consensus) gives $297. Method 2: a 2.5% required FCF yield (versus the current 2.4%) on forward free cash flow of ~$2.05B (TTM $1,874M grown 9%) across ~281.4M shares gives $291. The midpoint is $294, roughly 6-7% above the $276.18 price on 2026-09-13 and well below the $326.13 sell-side average, because I will not pay the full historical quality premium for growth that is roughly half acquired rather than organic.